BPC-157 — 10mg

BPC-157 (Body Protection Compound 157) is a synthetic 15-amino acid peptide fragment originally isolated from human gastric juice. Unlike growth factors that act on single receptor families, BPC-157 operates through a multi-pathway convergence that makes it uniquely effective across tissue types. Its cytoprotective effects were first characterized in the GI tract, but subsequent research has extended these findings to tendons, ligaments, bone, muscle, and even neural tissue.

At the molecular level, BPC-157 activates VEGFR2 signaling to drive new vessel formation at wound sites, mobilizes FAK-paxillin complexes that govern cell adhesion and directional migration, and upregulates growth hormone receptor expression in fibroblasts — dramatically amplifying the healing cascade. This receptor upregulation effect is particularly significant: by increasing GH receptor density, the peptide sensitizes local tissue to systemic growth signals without altering circulating hormone levels.

Research in rodent models has demonstrated consistent improvements in tendon-to-bone repair, ligament reattachment speed, and fracture healing timelines. A 2025 pilot human IV study at 10–20mg reported a favorable safety profile with no serious adverse events. BPC-157 is currently classified as an FDA Category 2 bulk drug substance, reflecting both its research interest and its regulatory status as a compound under active scientific scrutiny.